{
    "clinical_study": {
        "@rank": "37056", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who\n      have advanced neuroendocrine tumors."
        }, 
        "brief_title": "Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors", 
        "completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Carcinoma of Unknown Primary", 
            "Neuroendocrine Carcinoma", 
            "Neuroendocrine Carcinoma of the Skin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Merkel Cell", 
                "Carcinoma, Neuroendocrine", 
                "Neuroendocrine Tumors", 
                "Neoplasms, Unknown Primary", 
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Basosquamous", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of irinotecan in terms of tumor response, time to tumor\n           progression, and survival in patients with advanced high grade neuroendocrine tumors.\n\n        -  Evaluate the dose limiting and nondose limiting toxicities of this treatment regimen in\n           this patient population.\n\n      OUTLINE: Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment\n      repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed until death.\n\n      PROJECTED ACCRUAL: A total of 10-31 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven metastatic or unresectable high grade neuroendocrine tumor\n             including:\n\n               -  Small cell carcinoma\n\n               -  Large cell neuroendocrine carcinoma\n\n               -  Other high grade neuroendocrine carcinomas without specification to cell size\n\n               -  No lung only involvement without any other primary site\n\n          -  No primary small cell lung cancer with or without metastases\n\n          -  Bidimensionally measurable disease with at least one lesion measuring at least 1 cm\n             by 1 cm\n\n          -  High grade tumor indicated by at least one of the following:\n\n               -  Growth pattern suggestive of neuroendocrine differentiation\n\n               -  Mitotic rate greater than 15 mitoses per 10 hpf\n\n               -  Presence of abundant necrosis\n\n          -  Immunohistochemical evidence of neuroendocrine differentiation by positive staining\n             for chromogranin, synaptophysin, or neuron specific enolase if no classic microscopic\n             appearance of small cell carcinoma\n\n          -  No low grade neuroendocrine tumors (e.g., carcinoid tumors, pancreatic endocrine\n             tumors) and atypical tumors\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm^3\n\n          -  Granulocyte count at least 1,500/mm^3\n\n          -  Platelet count at least 75,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than upper limit of normal (ULN)\n\n          -  SGOT no greater than 5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No myocardial infarction within the past 6 months\n\n          -  No uncontrolled congestive heart failure requiring therapy\n\n        Other:\n\n          -  No active or uncontrolled infection\n\n          -  HIV negative\n\n          -  No psychiatric or other disorder that would preclude study\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  Not specified\n\n        Chemotherapy\n\n          -  No more than 2 prior chemotherapy regimens\n\n          -  No prior camptothecins\n\n        Endocrine therapy\n\n          -  Not specified\n\n        Radiotherapy\n\n          -  Not specified\n\n        Surgery\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004922", 
            "org_study_id": "99-041", 
            "secondary_id": [
                "CDR0000067605", 
                "NCI-G00-1683"
            ]
        }, 
        "intervention": {
            "intervention_name": "irinotecan hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Camptothecin"
            ]
        }, 
        "keyword": [
            "newly diagnosed carcinoma of unknown primary", 
            "recurrent carcinoma of unknown primary", 
            "stage III neuroendocrine carcinoma of the skin", 
            "recurrent neuroendocrine carcinoma of the skin", 
            "neuroendocrine carcinoma"
        ], 
        "lastchanged_date": "June 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-99041"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Sunil Sharma, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004922"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}